HCV in CKD: 2018 KDIGO guideline summary

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have shifted with the advent of highly effective direct-acting antivirals (DAAs) for HCV in patients with chronic kidney disease (CKD).

Key points

  • HCV screening recommended at CKD diagnosis, on initiation of dialysis, before transplant, and every 6 months during in-center hemodialysis.
  • HCV treatment in CKD:
    • Interferon-free regimen preferred.
    • Consider HCV genotype/subtype, viral load, treatment history, drug interactions, renal function, hepatic fibrosis stage, kidney/liver transplant candidacy, and comorbidities.
    • Patients with estimated glomerular filtration rate 2 should receive ribavirin-free DAA-based therapy.
    • Test for comorbid HBV.
  • Managing HCV before/after kidney transplant (KT):
    • Evaluate KT candidates for liver disease severity and portal hypertension. Consider combined liver/kidney transplant in settings of decompensated cirrhosis, with subsequent antiviral therapy.
    • KT recipients should receive a DAA-based regimen while considering drug interactions with immunosuppressive therapy. Monitor calcineurin inhibitor levels during/after treatment.
    • Base antiviral timing (before vs after KT) on donor type, wait-list times, HCV genotype, and fibrosis severity.
  • Managing HCV-associated glomerular disease: perform kidney biopsy.
    • Use DAAs in presence of stable kidney function and/or non-nephrotic proteinuria.
    • Add-on immunosuppression recommended for cryoglobulinemic flare, nephrotic syndrome, or rapidly progressive kidney failure.
    • Add rituximab in patients with histologically active glomerular disease who do not respond to antivirals.